Safety, efficacy, and dosing comparison of once-daily OROS hydromorphone and immediate-release hydromorphone in patients with chronic non-cancer pain

被引：0
|
作者：
Bornhovd, K.
Richarz, U.
Berliner, M. N.
Thipphawong, J.
机构：
[1] Janssen Cilag Germany, Med & Sci Affairs, Neuss, Germany
[2] Janssen Cilag Europe, Med Affairs, Baar, Switzerland
[3] Univ Klinikum Gieben, Med Klin & Poliklin 3, Rodthohl, Germany
[4] ALZA Corp, Med Res, Mountain View, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：562 / 562
页数：1
相关论文
共 50 条
  • [11] An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS1 hydromorphone in patients with chronic cancer pain
    Hanna M.
    Tuca A.
    Thipphawong J.
    BMC Palliative Care, 8 (1)
  • [12] Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain
    Wallace, M.
    Rauck, R. L.
    Moulin, D.
    Thipphawong, J.
    Khanna, S.
    Tudor, I. C.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2008, 36 (02) : 343 - 352
  • [13] A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain
    Bruera, E
    Sloan, P
    Mount, B
    Scott, J
    SuarezAlmazor, M
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 1713 - 1717
  • [14] Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
    Hale, Martin E.
    Nalamachu, Srinivas R.
    Khan, Arif
    Kutch, Michael
    JOURNAL OF PAIN RESEARCH, 2013, 6 : 319 - 329
  • [15] A Randomized Study to Demonstrate Noninferiority of Once-Daily OROS® Hydromorphone with Twice-Daily Sustained-Release Oxycodone for Moderate to Severe Chronic Noncancer Pain
    Binsfeld, Heinrich
    Szczepanski, Leszek
    Waechter, Sandra
    Richarz, Ute
    Sabatowski, Rainer
    PAIN PRACTICE, 2010, 10 (05) : 404 - 415
  • [16] Once-Daily OROS Hydromorphone for Management of Cancer Pain: An Open-Label, Multi-Center, Non-Interventional Study
    Park, Cheol Kyu
    Kang, Hyun-Wook
    Oh, In-Jae
    Kim, Young-Chul
    Kim, Yeo-Kyeoung
    Na, Kook-Joo
    Ahn, Sung-Ja
    Kim, Tae Ok
    Choi, Young Jin
    Song, Geun Am
    Lee, Min Ki
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2016, 31 (12) : 1914 - 1921
  • [17] Long-term efficacy and safety of once-daily oral extended-release hydromorphone.
    Swanton, R
    Buckley, B
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1068 - 1068
  • [18] Dose Equivalence of Immediate-Release Hydromorphone and Once-Daily Osmotic-Controlled Extended-Release Hydromorphone: A Randomized, Double-Blind Trial Incorporating a Measure of Assay Sensitivity
    Cruciani, Ricardo A.
    Katz, Nathaniel
    Portenoy, Russell K.
    JOURNAL OF PAIN, 2012, 13 (04): : 379 - 389
  • [19] Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: Two randomized controlled trials
    Grosset, AB
    Roberts, MS
    Woodson, ME
    Shi, MG
    Swanton, RE
    Reder, RF
    Buckley, BJ
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 29 (06) : 584 - 594
  • [20] A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients
    Inoue, Satoshi
    Saito, Yoji
    Tsuneto, Satoru
    Aruga, Etsuko
    Takahashi, Hiroshi
    Uemori, Mitsutoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (06) : 542 - 547
12345